Evidence map›Paper›PMID 37111782›Full record

ArticlePharmaceutics2023

Formulation and Characterization of Electrospun Nanofibers for Melatonin Ocular Delivery.

Alessia Romeo, Adrienn Kazsoki, Safaa Omer, Balázs Pinke, László Mészáros, Teresa Musumeci, Romána Zelkó

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Overview of Recent Advances in Nano-Based Ocular Drug Delivery.International journal of molecular sciences · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessia RomeoDepartment of Drug and Health Sciences, Laboratory of Drug Delivery Technology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Adrienn KazsokiUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Högyes Endre utca 7-9, H-1092 Budapest, Hungary.
Safaa OmerUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Högyes Endre utca 7-9, H-1092 Budapest, Hungary.
Balázs PinkeDepartment of Polymer Engineering, Faculty of Mechanical Engineering, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
László MészárosDepartment of Polymer Engineering, Faculty of Mechanical Engineering, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
Teresa MusumeciDepartment of Drug and Health Sciences, Laboratory of Drug Delivery Technology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0003-2299-7780
Romána ZelkóUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Högyes Endre utca 7-9, H-1092 Budapest, Hungary.ORCID 0000-0002-5419-9137

Funding

Ministry for Culture and Innovation ÚNKP-21-4-II-SE-20Ministry for Culture and Innovation ÚNKP-22-4-II-SE-29
6 · The paper itself

Abstract

The poor ocular bioavailability of melatonin (MEL) limits the therapeutic action the molecule could exert in the treatment of ocular diseases. To date, no study has explored the use of nanofiber-based inserts to prolong ocular surface contact time and improve MEL delivery. Here, the electrospinning technique was proposed to prepare poly (vinyl alcohol) (PVA) and poly (lactic acid) (PLA) nanofiber inserts. Both nanofibers were produced with different concentrations of MEL and with or without the addition of Tween

Indexed as

electrospinningin vitro dissolution studynanofibersocular deliveryocular insertPLAPVA

Identifiers

PMID37111782
PMCPMC10143234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.